BioSpace News Archive

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the European Patent Office has communicated its intention to grant a European patent titled ‘Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors’.

Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy

Geneos Therapeutics announced that its personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma.

Cyxone, a Swedish biotech in autoimmune diseases, announced that an order of more Rabeximod substance will be placed earlier than expected with the primary objective of providing optimal conditions for conducting the clinical phase IIb trial.

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC)

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announces the appointment of Peter Murphy to the newly created role of Chief Commercial Officer.

OurCrowd, the global crowdfunding venture investing platform and Israel’s leading venture investor, will feature Dr. Ferid Murad, 1998 Nobel prize winner in medicine, among the experts at the OurCrowd Global Investor Summit on Feb. 13.

OraSure Technologies, Inc. has scheduled its regular earnings conference call covering 2019 fourth quarter financial results, updated financial guidance and certain business developments for 5:00 pm ET on Wednesday, February 19, 2020..

Net sales were $10.2 billion, down 15% versus pro forma results in the year-ago period, primarily driven by lower local prices in all operating segments due to a decline in global energy prices.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 41,279,090 common shares of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares of the Company (the “Offering”